248 related articles for article (PubMed ID: 17679700)
41. Cardiovascular safety of rosiglitazone.
Krall RL
Lancet; 2007 Jun; 369(9578):1995-1996. PubMed ID: 17574083
[No Abstract] [Full Text] [Related]
42. New use of rosiglitazone decreased following publication of a meta-analysis suggesting harm.
Shah BR; Juurlink DN; Austin PC; Mamdani MM
Diabet Med; 2008 Jul; 25(7):871-4. PubMed ID: 18644075
[TBL] [Abstract][Full Text] [Related]
43. [Doubts as to the cardiovascular safety of rosiglitazone].
Hoekstra JB; Bossuyt PM; de Vries JH
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1449-50. PubMed ID: 17633972
[TBL] [Abstract][Full Text] [Related]
44. Critics press FDA to act on evidence of rosiglitazone's cardiac safety issues.
Mitka M
JAMA; 2010 Jun; 303(23):2341-2. PubMed ID: 20551399
[No Abstract] [Full Text] [Related]
45. Diabetes: making sense of the rosiglitazone controversy.
Farkouh ME; Fuster V
Nat Rev Cardiol; 2010 Jul; 7(7):366-7. PubMed ID: 20577297
[TBL] [Abstract][Full Text] [Related]
46. Editorial: What have we lost in the wake of the rosiglitazone controversy?
Zarich SW; Nesto RW
Endocr Pract; 2009 Apr; 15(3):273-4. PubMed ID: 19364699
[No Abstract] [Full Text] [Related]
47. Rosiglitazone, marketing, and medical science.
Moynihan R
BMJ; 2010 Apr; 340():c1848. PubMed ID: 20375091
[No Abstract] [Full Text] [Related]
48. Reassessing the cardiovascular risks and benefits of thiazolidinediones.
Zinn A; Felson S; Fisher E; Schwartzbard A
Clin Cardiol; 2008 Sep; 31(9):397-403. PubMed ID: 18781598
[TBL] [Abstract][Full Text] [Related]
49. Rosiglitazone or pioglitazone in type 2 diabetes?
de Vries CS; Russell-Jones DL
BMJ; 2009 Aug; 339():b3076. PubMed ID: 19690344
[No Abstract] [Full Text] [Related]
50. The perfect storm--drug safety and rosiglitazone.
Hellman R
Endocr Pract; 2007; 13(3):217-8. PubMed ID: 17599850
[No Abstract] [Full Text] [Related]
51. Diabetes: Breaking news! Rosiglitazone and cardiovascular risk.
Kaul S; Diamond GA
Nat Rev Cardiol; 2010 Dec; 7(12):670-2. PubMed ID: 21102630
[No Abstract] [Full Text] [Related]
52. Panel recommends easing restrictions on rosiglitazone despite concerns about cardiovascular safety.
Mitka M
JAMA; 2013 Jul; 310(3):246-7. PubMed ID: 23860970
[No Abstract] [Full Text] [Related]
53. [Doubts as to the cardiovascular safety of rosiglitazone].
Wolffenbuttel BH
Ned Tijdschr Geneeskd; 2007 Oct; 151(40):2236-7; author reply 2237. PubMed ID: 17969577
[No Abstract] [Full Text] [Related]
54. Meta-analysis for rare events.
Cai T; Parast L; Ryan L
Stat Med; 2010 Sep; 29(20):2078-89. PubMed ID: 20623822
[TBL] [Abstract][Full Text] [Related]
55. Rosiglitazone and heart failure: the controversy and clinical implications.
Virk IS; Ruby RS; Tepper D
Congest Heart Fail; 2007; 13(5):293-5. PubMed ID: 17917497
[TBL] [Abstract][Full Text] [Related]
56. Rosiglitazone and the case for safety over certainty.
Juurlink DN
JAMA; 2010 Jul; 304(4):469-71. PubMed ID: 20584879
[No Abstract] [Full Text] [Related]
57. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death.
Shuster JJ; Jones LS; Salmon DA
Stat Med; 2007 Oct; 26(24):4375-85. PubMed ID: 17768699
[TBL] [Abstract][Full Text] [Related]
58. [Rosiglitazone--statistics for benefits and problems].
Hjelmesaeth J; Røislien J
Tidsskr Nor Laegeforen; 2007 Oct; 127(20):2702-3. PubMed ID: 17952157
[No Abstract] [Full Text] [Related]
59. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database.
Ziyadeh N; McAfee AT; Koro C; Landon J; Arnold Chan K
Clin Ther; 2009 Nov; 31(11):2665-77. PubMed ID: 20110009
[TBL] [Abstract][Full Text] [Related]
60. Revisiting the rosiglitazone story--lessons learned.
Rosen CJ
N Engl J Med; 2010 Aug; 363(9):803-6. PubMed ID: 20660395
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
